Human Immunoglobulin(pH4) for Intravenous Injection (Boya Bio)

静注人免疫球蛋白(pH4)（博雅生物制药）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHuman Immunoglobulin(pH4) for Intravenous Injection (Boya Bio)
Drug Alias Name博欣（液体）
ClassificationBiologics > Protein drugs > Immunoglobulin
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsX chain low immunoglobulinAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[4] 
Global Approved IndicationsX chain low immunoglobulinAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[4] 
Approved Indications in ChinaX chain low immunoglobulinAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[4] 
Original Approved Country/TerritoryMainland China
Original Approved Date1999/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBoya Bio-Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBoya Bio-Pharmaceutical Group Co Ltd
Inactive CompaniesGuangdong Danxia Biological Pharmaceutical Co Ltd
Active IndicationsX chain low immunoglobulinAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeJ06BA02
Related LinksN/A